Nigerian student happy to find himself, excellent education at MSU Texas
When Samuel Olatunde first dreamed of coming to America to attend college, he thought basketball would be a part of it.
Duke University came to mind. But Olatunde realized after some time that he was good in basketball in his area, but it wouldn't be his future occupation. He still wanted to come to the United States and found Midwestern State University and Wichita Falls.
'My dad's plan was always to send me abroad to study. He wanted me to go to the UK, but I wanted to go to the U.S.,' Olutunde said. 'I had heard of Texas but not Wichita Falls.'
Starting college in 2020 as the world was experiencing COVID-19, it was the online presence of MSU Texas that gained his attention. But he was excited to come to campus to continue his educational journey, and he earned his bachelor of science from McCoy College of Science, Mathematics and Engineering in December 2024. And he stayed here for graduate school.
He initially didn't want many friends and admitted he wasn't the best at socializing.
'That helped me academically. I became friends with my teachers, and they were supportive,' he said.
He finished with a double major in computer science and mathematics and embraced his chances to do research. His message to others would be to try research.
'You never know until you do it, and you might enjoy it," he said.
After grad school at MSU Texas, he hopes to land a job that involves research.
'It's amazing here at MSU,' Olatunde said. 'It was a beautiful journey. One of the best things for me was it was a smaller school and I had access to (faculty). The support you get here is great. I had a lot of ups and downs and went through a lot of growth. I continued to grow in school and socially.'
His favorite professors included associate professors of computer science Eduard Colmenares-Diaz and Terry Griffin, who was Samuel's adviser and got him started in research, and Marcos Lopez, associate professor of mathematics.
His first MSU experience was an online class from Tiffany Zeigler, and he learned much about the rules for writing papers.
'I slowly picked it up. I had a very terrible relationship with writing (as a youth), but I've understood I can be really good at it. It takes a lot mentally, and I tend to spend a whole lot of time writing," Olatunde said.
Graduation in December was a milestone for him. His parents — dad Sayo and mother Bukola — came to celebrate with him.
He said they always had high goals for him. It was quite a journey, but he showed that belief in him was not misplaced. He just wasn't destined to be an NBA star.
'They would always help and support me, and here my confidence has grown socially and academically. I'm more outspoken and not afraid. (MSU) has helped me grow holistically in every aspect of my life,' Olutunde said.
More: MSU schedules health fair
More: Wichita Falls restaurant inspections: How did they do Feb. 12-24?
This article originally appeared on Wichita Falls Times Record News: Nigerian student happy to find himself, excellent education at MSU Texas
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study
(Reuters) -Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in some patients tested in a late-stage study, the company said on Wednesday.
Time Magazine
35 minutes ago
- Time Magazine
Sierra Leone Is Battling an Mpox Outbreak. What Happens Next Affects Us All
A dangerous mpox outbreak is unfolding in Sierra Leone. In just the first week of May, cases rose by 61%, and suspected cases surged by 71%. Roughly half of all confirmed mpox cases in Africa now come from this small West African nation. The virus is moving widely, across geographies, genders, and age groups. And the virus is changing. Genomic analysis has revealed a fast-moving new variant of mpox—called G.1—that likely emerged in late November. At first it circulated silently but has since taken hold and quickly began sustained human-to-human transmission. Cases have been doubling every two weeks. Estimates suggest more than 11,000 people in Sierra Leone may already be infected. This is how outbreaks become epidemics, and mpox, as a pandemic, could be brutal. Mpox (formerly known as monkeypox) belongs to the same viral family as smallpox. It causes a disease that can be painful, disfiguring, and debilitating, particularly in children. In Sierra Leone, nearly all patients present with severe rashes, and about a quarter have required hospitalization; in some, the disease has progressed to necrotizing lesions. It's no longer rare, no longer contained to the LGBTQ community, and it has already reached more than 100 countries. Read More: Tedros Adhanom Ghebreyesus: Global-health architect Sierra Leone has been here before, at the epicenter of a disease outbreak while the world looked away. In 2014, Ebola swept through the West African region. A single mutation supercharged its spread just as it reached Sierra Leone. Tens of thousands died. Health systems collapsed. The global cost soared into the billions. The lesson? Delay is deadly. As infectious disease researchers, we've lived that lesson. For two decades, we've worked alongside colleagues across Africa and around the world to build faster, smarter ways to detect and respond to outbreaks. We were on the ground during Ebola, Zika, the COVID-19 pandemic, and recently Marburg—plus, many outbreaks that never made the news because they were stopped in time. Together, we've built technologies that track viruses in real time and trained thousands of frontline workers to use them. What once took months, we can now do in days. And now, in Sierra Leone, we are putting that progress to the test. This time, Sierra Leone isn't waiting for others to step in to do testing and sequencing—it's leading. Within days of the outbreak's escalation, local public-health teams and scientists under the leadership of Sierra Leone's National Public Health Agency—working with international partners including ourselves—expanded testing, began sequencing the virus, analyzed its evolution, and shared data in real-time. They also launched robust social mobilization and contact tracing that are helping to slow the spread. To stay ahead of the virus, teams in Sierra Leone are using powerful new tools. One is Lookout, our real-time national platform that fuses genomic, diagnostic, clinical, and epidemiological data into a single cloud-based system. As more data come in, Lookout gives health officials a live, evolving map of the outbreak, showing where it's spreading, how it's changing, and where to act next. Lookout is just one example of the infrastructure that teams in the U.S. and Africa have co-created through decades of collaboration. It belongs to a broader system called Sentinel, an outbreak detection and response network we co-lead, launched with support from the Audacious Project, a collaborative funding initiative housed at TED. Sentinel is just one part of a larger movement: scientists, engineers, public health leaders, industry partners, and frontline workers working together to build faster, smarter systems to stop outbreaks before they explode. But even the best systems can't run without support. Earlier this year, the U.S. canceled all funding to Sierra Leone and halted a $120 million initiative by the U.S. Centers for Disease Control and Prevention (CDC) aimed at strengthening epidemic preparedness in the country. The Africa CDC, U.S. CDC, World Health Organization (WHO) and other organizations continue to offer vital support, but with far fewer resources than before. Philanthropic and industry partners, including the ELMA Relief Foundation, Danaher, and Illumina, have admirably stepped in, but they cannot fill the gap alone. Today, local teams are doing so much right—with nearly everything stacked against them. The warning signs are flashing. But their resources are running out. It's tempting to believe this isn't our problem. But thanks to collaborative sequencing efforts, we know the G.1 variant spreading in Sierra Leone has already been detected in at least five patients across multiple U.S. states—Massachusetts, Illinois, and California—and in Europe. It may seem distant—like COVID-19 did at first—but it's not. Yes, vaccines exist, and they are expected to be effective against this new variant. But supply is limited, distribution is deeply inequitable, and the vaccines themselves present challenges—from limited clinical data and uncertain duration of protection to storage requirements—that make large-scale campaigns far from straightforward. West Africa has received only a fraction of the doses it needs. Without both vaccine access and real-time tracking, we're flying blind. Surveillance isn't a luxury. It's our first and best line of defense. Sierra Leone is showing the world what preparedness looks like. But it shouldn't have to stand alone. We can wait—again—until the virus spreads further. Or we can act now, support the leaders in Sierra Leone already responding, and get them the resources they need—like diagnostics, clinical support, vaccines, sequencing reagents, and frontline outbreak response—to save lives and cut this outbreak short. We've seen how the story of viral outbreaks can unfold. This time, with the present mpox epidemic in Sierra Leone, we still have a chance to change the ending.
Yahoo
2 hours ago
- Yahoo
Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
Both vaccine candidates induced robust immune responses across all antigens tested No new safety signals were observed and both vaccine candidates were well tolerated consistent with past trials Novavax continues to pursue partnering opportunities to advance further development of these programs GAITHERSBURG, Md., June 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced results of the initial cohort of its COVID-19-Influenza Combination (CIC) and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) Phase 3 trial that showed both the CIC and flu vaccine candidates induced immune responses similar to licensed comparators Nuvaxovid® and Fluzone HD, respectively. This cohort was designed to provide descriptive data on three flu strains (H1N1, H3N2, B) and SARS-CoV-2 (COVID-19) to inform a future registrational Phase 3 program. "Both our combination and stand-alone flu vaccine candidates induced robust immune responses and were well tolerated," said Ruxandra Draghia-Akli, MD, PhD, Executive Vice President and Head of Research and Development, Novavax. "This data set adds to findings from our Phase 2 trial and will help inform discussions with potential partners." Both stand-alone flu and CIC vaccine candidates induced robust immune responses to the vaccine strains (2.4-5.7-fold over baseline). Both vaccine candidates were well tolerated and saw reactogenicity comparable to authorized comparators. Nearly all (>98%) solicited adverse events were mild or moderate in severity. This descriptive trial was designed to evaluate the safety and immunogenicity of the CIC and stand-alone flu vaccine candidates compared to Nuvaxovid and Fluzone HD in approximately 2,000 adults aged 65 and older. This trial was not adequately powered to demonstrate statistical significance. These results build on previous Phase 2 data. About NovavaxNovavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit and LinkedIn for more information. Forward-Looking Statements Statements herein relating to the future of Novavax, its operating plans and prospects, its partnerships, and the potential for its CIC and stand-alone influenza vaccine to be used with a partner in a registrational Phase 3 program, are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges pursuing additional partnership opportunities; challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities; challenges or delays in conducting clinical trials or studies for its product candidates; challenges or delays in obtaining regulatory authorization for its product candidates, including for future COVID-19 variant strain changes, its CIC vaccine candidate, its stand-alone influenza vaccine candidate or other product candidates; manufacturing, distribution or export delays or challenges; Novavax's substantial dependence on Serum Institute of India Pvt. Ltd. and Serum Life Sciences Limited for co-formulation and filling Novavax's COVID-19 vaccine and the impact of any delays or disruptions in their operations; difficulty obtaining scarce raw materials and supplies including for its proprietary adjuvant; resource constraints, including human capital and manufacturing capacity; constraints on Novavax's ability to pursue planned regulatory pathways, alone or with partners; challenges in implementing its global restructuring and cost reduction plan; challenges in obtaining commercial adoption and market acceptance of its updated COVID-19 vaccine or any COVID-19 variant strain containing formulation, or for its CIC vaccine candidate and stand-alone influenza vaccine candidate or other product candidates; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities, including requirements to deliver doses that may require Novavax to refund portions of upfront and other payments previously received or result in reduced future payments pursuant to such agreements and challenges in amending or terminating such agreements; challenges related to the seasonality of vaccinations against COVID-19; challenges related to the demand for vaccinations against COVID-19 or influenza; challenges in identifying and successfully pursuing innovation expansion opportunities; Novavax's expectations as to expenses and cash needs may prove not to be correct for reasons such as changes in plans or actual events being different than its assumptions; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Contacts: InvestorsLuis Sanay, CFA240-268-2022ir@ MediaGiovanna Chandler202-709-5563media@ View original content to download multimedia: SOURCE Novavax, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
